Repositorio
Institucional

Sorensen, Ricardo U.

Edgar, J. David M.

Overview of antibody-mediated immunity to S-pneumoniae: pneumococcal infections, pneumococcal immunity assessment, and recommendations for IG product evaluation

WILEY

TRANSFUSION

en

Streptococcus pneumoniae (S. pneumoniae) strains colonize the nasopharynx and can cause mucosal infections in the upper airway and middle ear, pneumonias, and invasive infections like bacteremia, sepsis, and meningitis. Over 90 serotypes, defined by the structure of their capsular polysaccharides, are known. Twenty-three of these serotypes cause most infections and several of these serotypes can develop antibiotic resistance. Susceptibility factors that increase the susceptibility to S. pneumoniae mucosal and invasive infections include all forms of primary and secondary antibody deficiencies. Many patients affected by one of these deficiencies benefit from the regular administration of human gamma globulin (IgG) preparations. Donors of plasma units used to prepare human IgG have varying concentrations of IgG antibodies against relevant S. pneumoniae serotypes. These antibodies are developed in response to colonization and common subclinical infections and by routine vaccination with S. pneumoniae polysaccharide vaccines. The presence of an adequate concentration of these protective antibodies against all prevalent serotypes needs to be determined to assure the effectiveness of human IgG. All presently available methods to assess IgG antibodies against S. pneumoniae capsular polysaccharides have advantages and pitfalls that are analyzed in this review. In vitro testing does not provide a complete or necessarily accurate measurement of the effectiveness of antibodies in vivo. For regulatory purposes, caution needs to be used in the interpretation of currently available assays that measure pneumococcal antibody levels. Monitoring S. pneumoniae infections in patients treated with IgG and tracing information about IgG lots used to treat these patients should be encouraged.

Artículo original

RUS participates in the CSL-Behring Speaker's Bureau, JDME has a financial relationship with Shire UK, Ltd. through a consulting agreement and speaker fees 2018, and with Octapharma through a consulting agreement and speaker fees 2017/18. Additionally, JDME has a financial relationship with Grifols, which includes attendance expenses for ESID 2017, and both a nonfinancial and a financial relationship with ALK Abello, including speaker fee and attendance at BSACI 2016.

RUS participa en la Oficina de Conferencias de CSL-Behring. JDME mantiene una relación financiera con Shire UK, Ltd. mediante un acuerdo de consultoría y honorarios por ponencias en 2018, y con Octapharma mediante un acuerdo de consultoría y honorarios por ponencias en 2017/18. Además, JDME mantiene una relación financiera con Grifols, que incluye los gastos de asistencia a ESID 2017, y una relación financiera y no financiera con ALK Abello, que incluye los honorarios por ponencias y la asistencia a BSACI 2016.

10.1111/trf.15044

pdf

http://dx.doi.org/10.1111/trf.15044

Hematology

Enfermedades Infecciosas

Inmunología

Biotecnología Relacionada con la Salud

WOS:000452475900010

Overview of antibody-mediated immunity to <i>S-pneumoniae:</i> pneumococcal infections, pneumococcal immunity assessment, and recommendations for IG product evaluation

Artículo original

version publicada

WILEY

TRANSFUSION

Hematología

0041-1132

en

Shire UK, Ltd#Octapharma#

Shire UK

Grifols

ALK Abello

RUS participates in the CSL-Behring Speaker's Bureau, JDME has a financial relationship with Shire UK, Ltd. through a consulting agreement and speaker fees 2018, and with Octapharma through a consulting agreement and speaker fees 2017/18. Additionally, JDME has a financial relationship with Grifols, which includes attendance expenses for ESID 2017, and both a nonfinancial and a financial relationship with ALK Abello, including speaker fee and attendance at BSACI 2016.

pdf

hibrida

acceso abierto

acceso abierto

S251

S273